Bone marrow or stem cell transplantation is performed for a variety of cancers. We
require the transplantation to occur before we evaluate it under these listings. We
do not need to restrict our determination of the onset of disability to the date of
transplantation (113.05 or 113.06). We may be able to establish an earlier onset date
of disability due to your transplantation if the evidence in your case record supports
such a finding.
1. Acute leukemia (including all types of lymphoblastic lymphomas and JCML) or accelerated
or blast phase of CML. If you undergo bone marrow or stem cell transplantation for any of these disorders,
we will consider you to be disabled until at least 24 months from the date of diagnosis
or relapse, or at least 12 months from the date of transplantation, whichever is later.
2. Lymphoma or chronic phase of CML. If you undergo bone marrow or stem cell transplantation for any of these disorders,
we will consider you to be disabled until at least 12 months from the date of transplantation.
3. Evaluating disability after the appropriate time period has elapsed. We consider any residual impairment(s), such as complications arising from:
a. Graft-versus-host (GVH) disease.
b. Immunosuppressant therapy, such as frequent infections.
c. Significant deterioration of other organ systems.
113.01 Category of Impairments, Cancer (Malignant Neoplastic Diseases
113.03 Malignant solid tumors. Consider under a disability:
A. For 24 months from the date of initial diagnosis. Thereafter, evaluate any residual
impairment(s) under the criteria for the affected body system.
OR
B. For 24 months from the date of recurrence of active disease. Thereafter, evaluate
any residual impairment(s) under the criteria for the affected body system.
113.05 Lymphoma excluding all types of lymphoblastic lymphomas--(113.06). (See 113.00K1.)
A. Non-Hodgkin lymphoma (including Burkitt’s and anaplastic large cell), with either
1 or 2:
1. Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis.
Consider under a disability for 24 months from the date of diagnosis. Thereafter,
evaluate under 113.05A2, or any residual impairments(s) under the criteria for the
affected body system.
2. Persistent or recurrent following initial anticancer therapy.
OR
B. Hodgkin lymphoma, with either 1 or 2:
1. Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis.
Consider under a disability for 24 months from the date of diagnosis. Thereafter,
evaluate under 113.05B2, or any residual impairment(s) under the criteria for the
affected body system.
2. Persistent or recurrent following initial anticancer therapy.
OR
C. With bone marrow or stem cell transplantation. Consider under a disability until
at least 12 months from the date of transplantation. Thereafter, evaluate any residual
impairment(s) under the criteria of the affected body system.
OR
D. Mantle cell lymphoma.
113.06 Leukemia. (See 113.00K2.)
A. Acute leukemia (including all types of lymphoblastic lymphomas and juvenile chronic
myelogenous leukemia (JCML)). Consider under a disability until at least 24 months
from the date of diagnosis or relapse, or at least 12 months from the date of bone
marrow or stem cell transplantation, whichever is later. Thereafter, evaluate any
residual impairment(s) under the criteria for the affected body system.
OR
B. Chronic myelogenous leukemia (except JCML), as described in 1 or 2:
1. Accelerated or blast phase (see 113.00K2b). Consider under a disability until at
least 24 months from the date of diagnosis or relapse, or at least 12 months from
the date of bone marrow or stem cell transplantation, whichever is later. Thereafter,
evaluate any residual impairment(s) under the criteria for the affected body system.
2. Chronic phase, as described in a or b:
a. Consider under a disability until at least 12 months from the date of bone marrow
or stem cell transplantation. Thereafter, evaluate any residual impairment(s) under
the criteria for the affected body system.
b. Progressive disease following initial antineoplastic therapy.
113.09 Thyroid gland.
A. Anaplastic (undifferentiated) carcinoma.
OR
B. Carcinoma with metastases beyond the regional lymph nodes progressive despite radioactive
iodine therapy.
OR
C. Medullary carcinoma with metastases beyond the regional lymph nodes.
113.12 Retinoblastoma.
A. With extension beyond the orbit.
OR
B. Persistent or recurrent following initial anticancer therapy.
OR
C. With regional or distant metastases.
113.13 Nervous system. (See 113.00K4.)
Primary central nervous system (CNS; that is, brain and spinal cord) cancers, as described
in A, B, or C:
A. Glioblastoma multiforme, ependymoblastoma, and diffuse intrinsic brain stem gliomas
(see 113.00K4a).
B. Any Grade III or Grade IV CNS cancer (see 113.00K4b), including astrocytomas, sarcomas,
and medulloblastoma and other primitive neuroectodermal tumors (PNETs).
C. Any primary CNS cancer, as described in 1 or 2:
1. Metastatic.
2. Progressive or recurrent following initial anticancer therapy.
113.21 Neuroblastoma.
A. With extension across the midline.
OR
B. With distant metastases.
OR
C. Recurrent.
OR
D. With onset at age 1 year or older.
113.29 Malignant melanoma (including skin, ocular, or mucosal melanomas), as described in either A, B, or C:
A. Recurrent (except an additional primary melanoma at a different site, which is
not considered to be recurrent disease) following either 1 or 2:
1. Wide excision (skin melanoma).
2. Enucleation of the eye (ocular melanoma).
OR
B. With metastases as described in 1, 2, or 3:
1. Metastases to one or more clinically apparent nodes; that is, nodes that are detected
by imaging studies (excluding lymphoscintigraphy) or by clinical evaluation (palpable).
2. If the nodes are not clinically apparent, with metastases to four or more nodes.
3. Metastases to adjacent skin (satellite lesions) or distant sites (for example,
liver, lung, or brain).
OR
C. Mucosal melanoma.